Respiratory Biologics Market Report 2025

The respiratory biologics market size has grown rapidly in recent years. It will grow from $6.38 billion in 2024 to $7.41 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing prevalence of respiratory diseases, rising adoption of personalized medicine, growing healthcare expenditure globally, increasing awareness and diagnosis rates of respiratory conditions, and an expanding geriatric population with respiratory disorders.

The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $13.51 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to the rising prevalence of asthma and COPD, increasing adoption of biologic therapies, increasing R&D spending, increasing demand for non-invasive drug delivery, and expansion of reimbursement policies. Major trends in the forecast period include adoption of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery methods, regulatory approvals, strategic collaborations and acquisitions among key players, and integration of artificial intelligence in drug discovery and development.

The forecast of 16.2% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff increases could impact U.S. pulmonology practices by inflating costs of monoclonal antibody treatments for severe asthma and chronic obstructive pulmonary disease imported from the Netherlands and Belgium, resulting in reduced biologic therapy access and higher respiratory care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing levels of air pollution are expected to drive the expansion of the respiratory biologics market in the coming years. Air pollution refers to the presence of harmful substances, such as gases, particulate matter, and biological molecules, in the atmosphere, which can negatively impact both human health and the environment. The rise in air pollution is largely due to increased industrialization and urbanization, resulting in higher emissions from factories, vehicles, and construction activities. Respiratory biologics help address the health effects of air pollution by offering targeted therapies that reduce inflammation and enhance lung function in individuals exposed to airborne pollutants. For example, in January 2025, the United States Environmental Protection Agency (EPA) reported that over 66 million tons of pollutants were released into the atmosphere in 2023. Additionally, according to the United Nations Environment Programme in September 2022, air pollution causes 7 million premature deaths each year, and 99% of the global population breathes polluted air. Consequently, the rising levels of air pollution are driving the growth of the respiratory biologics market.

Leading companies in the respiratory biologics market are focusing on developing innovative biologic therapies, such as targeted immune treatments for chronic respiratory diseases, to provide precise treatments that reduce inflammation and enhance lung function. These targeted immune therapies for chronic respiratory diseases are designed to manage the body’s immune system to reduce swelling and alleviate breathing difficulties in long-term lung conditions. For example, in September 2024, Sanofi S.A., a pharmaceutical company based in France, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. This approval was a significant milestone, making Dupixent the first biologic medication authorized in the US for this particular group of COPD patients.

In February 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. With this acquisition, GSK aims to enhance its respiratory and immunology portfolio by gaining access to Aiolos Bio’s innovative treatments for inflammatory and immune-mediated diseases. Aiolos Bio is a US-based company focused on developing biological therapies for respiratory and inflammatory conditions.

Major players in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The respiratory biologics market research report is one of a series of new reports that provides respiratory biologics market statistics, including the respiratory biologics industry global market size, regional shares, competitors with the respiratory biologics market share, detailed respiratory biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the respiratory biologics industry. These respiratory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Respiratory biologics are a class of targeted therapies derived from living organisms, used to treat chronic respiratory conditions. These biologics typically focus on specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and enhance breathing. They are primarily prescribed to patients with severe, uncontrolled respiratory diseases that do not respond adequately to standard treatments such as inhaled corticosteroids and bronchodilators.

The primary conditions treated with respiratory biologics include asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma is a chronic inflammatory disorder of the airways that leads to breathing problems, wheezing, and coughing due to airway narrowing and heightened sensitivity. These biologics are available in various forms, such as intravenous and subcutaneous injections, and are distributed through different channels, including hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.